Cogent Biosciences Files NDA for Bezuclastinib in GIST
WALTHAM, Mass. and BOULDER, Colo., April 1, 2026 Cogent Biosciences, Inc. has announced the successful submission of a New...
Alzheimer’s Disease Bio-Pharma biologics biopharma biopharma innovation Biotechnology cancer therapy Cell Therapy cGxP Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development FDA fda approval FDA clearance GCP Gene Therapy GMP GMP compliance Immuno-Oncology immunology Immunotherapy Medical Devices MedTech medtech innovation Monoclonal Antibody Oncology oncology innovation Orphan Drug orphan drug designation patient access Phase 1 trial Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine regulatory approval regulatory compliance targeted therapy
WALTHAM, Mass. and BOULDER, Colo., April 1, 2026 Cogent Biosciences, Inc. has announced the successful submission of a New...
Waltham, Massachusetts & Boulder, Colorado, January 26, 2026 — Cogent Biosciences, Inc. announced that the U.S. Food and Drug...
Waltham, Massachusetts & Boulder, Colorado | December 30, 2025 — Cogent Biosciences, Inc. has announced the submission of a...
Dateline — WALTHAM, Mass. and BOULDER, Colo., November 11, 2025:Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company developing precision...
